Genmab Board of Directors Chairman to Step Down

Copenhagen, Denmark; February 21, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that the Chairman of the Board of Directors, Mr. Mats Pettersson, B.Sc., has decided to step down from the Board at Genmab A/S’ Annual General Meeting on March 26, 2020, when his election period is set to expire. Mr. Pettersson has led the company’s Board of Directors since his election in 2013 and will not be up for re-election at the company’s 2020 Annual General Meeting.

“I am extremely grateful to Mats for his strong leadership as Chairman and for his service in overseeing our goals and strategies and monitoring our business performance over the last seven years,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “On behalf of the entire Board of Directors and the Executive Management Team, I’d like to thank Mats for his excellent contributions and wish him continued success.”

Subject to re-election at the 2020 Annual General Meeting, it is the Board of Director’s intention to appoint Ms. Deirdre P. Connelly as the new Chairman of the Board. Additionally, the Genmab Board of Directors expects to nominate a new candidate for election to join the Board at the 2020 Annual General Meeting.

“It has been an honor to lead the Genmab Board of Directors during these seven fantastic years and to have worked alongside Jan and the management team. Their passion for science and innovation and their clear vision of the future have positioned Genmab for continuous success,” said Mr. Pettersson. “Genmab now has all the resources to realize its vision of transforming cancer treatment, including a strong financial foundation, cutting-edge technology and highly skilled and dedicated teams.”  

About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of three approved antibodies: DARZALEX^® (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Arzerra^® (ofatumumab, under agreement with Novartis AG), for the treatment of certain chronic lymphocytic leukemia indications in the U.S., Japan and certain other territories and TEPEZZA™ (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development by Novartis for the treatment of relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody^® platform for generation of bispecific antibodies, the HexaBody^® platform, which creates effector function enhanced antibodies, the HexElect^® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody^® platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.